Oxford Biomedica PLC Directors Dealings / Market Share Purchases (0372D)
June 24 2021 - 8:05AM
UK Regulatory
TIDMOXB
RNS Number : 0372D
Oxford Biomedica PLC
24 June 2021
Directors Dealings / Market Share Purchases
Oxford, UK - 24 June 2021: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that two of the Company's
Non-Executive Directors have purchased shares in the Company.
As stated in the Oxford Biomedica 2021 Remuneration Policy which
was approved at the 2021 Annual General Meeting, an additional fee
of up to GBP50,000 per annum may be paid to any Non-Executive
Director recruited from or based in the United States to reflect
market levels of remuneration in the United States for
Non-Executive Directors, subject to their agreement that the after
tax amount of this additional fee will be applied in the
acquisition of Oxford Biomedica shares at market value, which must
be retained for at least 12 months from acquisition.
Dr. Heather Preston, Non-Executive Director of the Group, has
purchased 2,235 ordinary shares of 50p each ("Ordinary Shares") in
the Company on 23 June 2021 on the London Stock Exchange at a price
of 1288p under the terms of a market purchase agreement. Following
this purchase Dr. Heather Preston holds 2,235 Ordinary Shares
representing 0.003% of the Company.
Dr. Siyamak Rasty, Non-Executive Director of the Group, has
purchased 2,235 Ordinary Shares in the Company on 23 June 2021 on
the London Stock Exchange at a price of 1288p under the terms of a
market purchase agreement. Following this purchase Dr. Siyamak
Rasty holds 2,235 Ordinary Shares representing 0.003% of the
Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of ordinary shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Heather Preston
2. Reason for the notification
a. Position/status Non-Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP12.88 2,235
e. Aggregated information 2,235
* Aggregated volume GBP12.88
GBP28,786.80
* Price
* Aggregated total
f. Date of the transaction 2021-06-23
g. Place of the transaction London Stock Exchange, Main Market (XLON)
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Siyamak Rasty
2. Reason for the notification
a. Position/status Non-Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP12.88 2,235
e. Aggregated information 2,235
* Aggregated volume GBP12.88
GBP28,786.80
* Price
* Aggregated total
f. Date of the transaction 2021-06-23
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 82,591,804 Ordinary
Shares.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb, Sio
Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a three year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 670 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSEAFFLEFSEDM
(END) Dow Jones Newswires
June 24, 2021 08:05 ET (12:05 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024
